# PTM Combinatorial Space Theory

**Doc-Type:** Foundational White Paper | Version 1.0 | Updated 2025-12-24

---

## Abstract

This document establishes the theoretical and empirical foundation for understanding how post-translational modifications (PTMs) combine to produce immunogenic or non-immunogenic outcomes. Using hyperbolic (p-adic) geometry encoded via the 3-adic codon encoder, we characterize a **non-monotonic response surface** where neither too few nor too many concurrent PTMs produce immunogenicityâ€”only specific combinations at specific orders reach the "Goldilocks Zone" of 15-30% geometric shift that triggers autoimmune recognition.

**Applicability:** This framework applies to any human protein, any genetic background, and any disease context involving PTM-driven autoimmunity.

---

## 1. The Non-Monotonic Principle

### 1.1 Core Discovery

The relationship between PTM combination order and immunogenic potential is **non-monotonic**:

```
                          Geometric Shift (%)
                    0%   25%   50%   75%  100%  125%
                    â”‚     â”‚     â”‚     â”‚     â”‚     â”‚
  Order 1 (Single)  â”‚     â”‚     â”‚â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â”‚     â”‚  Mean: 69%
                    â”‚     â”‚     â”‚     â”‚     â”‚     â”‚
  Order 2 (Pair)    â”‚â–‘â–‘â–‘â–‘â–‘â”‚â–‘â–‘â–‘â–‘â–‘â”‚     â”‚     â”‚     â”‚  Mean: 25-30% *
                    â”‚     â”‚     â”‚     â”‚     â”‚     â”‚
  Order 3 (Triple)  â”‚     â”‚     â”‚â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â”‚  Mean: 75%+
                    â”‚     â”‚     â”‚     â”‚     â”‚     â”‚
  Order 4 (Quad)    â”‚     â”‚     â”‚     â”‚â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“  Mean: 90%+
                    â”‚     â”‚     â”‚     â”‚     â”‚     â”‚
                    â””â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”˜
                          â–²           â–²
                    GOLDILOCKS    TOO MUCH
                     (15-30%)    (>60%)

  * For specific antagonistic pairs (R-N, K-R)
```

### 1.2 Biological Interpretation

| Order | Geometric Outcome | Biological Fate | Immunogenic? |
|-------|-------------------|-----------------|--------------|
| **0** | No change (0%) | Normal self | No |
| **1** | Extreme shift (~70%) | Rapid degradation | No |
| **2** | Moderate shift (25-30%) | Presented as neo-epitope | **YES** |
| **3+** | Extreme shift (75%+) | Complete unfolding | No |

**Key Insight:** Immunogenicity requires a geometric perturbation that is:
- **Large enough** to be recognized as "different from self"
- **Small enough** to maintain structural integrity for antigen presentation

Only **specific pair combinations** achieve this balance through **antagonistic compensation**.

---

## 2. Universal Invariants

### 2.1 The Synergy Ratio

**Definition:** The ratio of combined effect to sum of individual effects.

```
Synergy Ratio = Effect(A+B) / [Effect(A) + Effect(B)]
```

**Empirical Values:**

| Combination Order | Synergy Ratio | Interpretation |
|-------------------|---------------|----------------|
| Pairs | 0.40 Â± 0.12 | Strongly antagonistic |
| Triples | 0.35 Â± 0.08 | More antagonistic |
| Quadruples | 0.30 Â± 0.10 | Maximally antagonistic |

**Invariant:** Combined effects are always **less than** the sum of parts (synergy ratio < 1.0).

### 2.2 The Span-Synergy Relationship

**Definition:** Relationship between residue distance and synergy ratio.

```
Synergy Ratio = Î± Ã— Span + Î²

Where:
  Î± = -0.023 (slope)
  Î² = 0.78 (intercept)
  RÂ² = 0.95
```

**Interpretation:**
- **Closer sites** (span 1-5): Stronger antagonism (ratio ~0.30)
- **Distant sites** (span 10-15): Weaker antagonism (ratio ~0.55)
- **Critical threshold:** Span > 15 residues â†’ effects become independent

### 2.3 Goldilocks Zone Boundaries

**Definition:** The range of geometric shift that produces immunogenic epitopes.

| Boundary | Value | Meaning |
|----------|-------|---------|
| Lower | 15% | Below this: too similar to self |
| Upper | 30% | Above this: too disrupted for presentation |
| Optimal | 22-27% | Highest immunogenicity |

**Zone Entry Probability by Order:**

| Order | Goldilocks Rate | Mechanism |
|-------|-----------------|-----------|
| Singles | <1% | Overshoot (too much shift) |
| Pairs | 8-12% | Antagonism brings into zone |
| Triples | <1% | Antagonism insufficient |
| Quadruples | 0% | Complete oversaturation |

---

## 3. Residue Pair Taxonomy

### 3.1 Immunogenic Pair Classes

Based on empirical analysis of 1500+ combinations:

| Pair Type | Primary PTM | Secondary PTM | Goldilocks Rate | Mechanism |
|-----------|-------------|---------------|-----------------|-----------|
| **K-R** | Acetylation | Citrullination | 7.9% | Charge neutralization |
| **R-N** | Citrullination | Deglycosylation | 12.5%* | Glycan shield removal |
| **K-N** | Acetylation | Deglycosylation | ~5% | Combined neutralization |

*From focused R-N analysis with citrullination-specific encoding

### 3.2 Non-Immunogenic Pair Classes

| Pair Type | Goldilocks Rate | Reason |
|-----------|-----------------|--------|
| S-S | 0% | Dual phosphorylation overshoots |
| S-T | 0% | Phospho-phospho too extreme |
| R-S | 0% | Charge inversion too dramatic |

### 3.3 The Critical Pair Principle

**Theorem:** For a protein to become immunogenic through PTM:

1. Two sites must be modified concurrently
2. The sites must be within 15 residues of each other
3. The PTM types must be **antagonistically complementary**

**Complementary Pairs:**
- Deimination (Râ†’Cit) + Glycan removal (Nâ†’D)
- Acetylation (Kâ†’Ac) + Deimination (Râ†’Cit)
- Acetylation (Kâ†’Ac) + Deamidation (Nâ†’D)

---

## 4. Mathematical Framework

### 4.1 Hyperbolic Embedding Space

Protein sequences are embedded in the PoincarÃ© ball via 3-adic codon encoding:

```
Sequence S = (câ‚, câ‚‚, ..., câ‚™) â†’ Embedding E = (eâ‚, eâ‚‚, ..., eâ‚™) âˆˆ ð”¹â¿

Where ð”¹â¿ is the n-dimensional PoincarÃ© ball with curvature c = 1
```

### 4.2 PTM Effect as Geometric Transformation

A PTM at position i transforms embedding eáµ¢ â†’ eáµ¢':

```
Centroid Shift = d_H(Î¼(E), Î¼(E'))

Where:
  Î¼(E) = (1/n) Î£ eáµ¢  (hyperbolic centroid)
  d_H = PoincarÃ© distance
```

### 4.3 Relative Shift

```
Relative Shift = Centroid Shift / ||Î¼(E)||

Goldilocks: 0.15 â‰¤ Relative Shift â‰¤ 0.30
```

### 4.4 Synergy Function

For modifications A and B:

```
S(A,B) = Effect(A âˆª B) / [Effect(A) + Effect(B)]

Empirical form:
  S(A,B) = Î± Ã— d(A,B) + Î²

Where d(A,B) is the sequence distance between sites
```

---

## 5. Predictive Model

### 5.1 Goldilocks Probability

Given a pair of modifiable sites (i, j) with residue types (Ráµ¢, Râ±¼):

```
P(Goldilocks | i, j) = f(Ráµ¢, Râ±¼) Ã— g(|i - j|) Ã— h(context)

Where:
  f(Ráµ¢, Râ±¼) = residue pair compatibility score
  g(|i - j|) = distance-dependent synergy factor
  h(context) = local sequence context modifier
```

### 5.2 Lookup Tables

**Residue Pair Scores f(Ráµ¢, Râ±¼):**

|     | R    | N    | K    | S    | T    |
|-----|------|------|------|------|------|
| R   | 0.02 | 0.12 | 0.08 | 0.00 | 0.01 |
| N   | -    | 0.03 | 0.05 | 0.02 | 0.02 |
| K   | -    | -    | 0.00 | 0.00 | 0.01 |
| S   | -    | -    | -    | 0.00 | 0.00 |
| T   | -    | -    | -    | -    | 0.00 |

**Distance Factor g(d):**

```
g(d) = max(0, 1 - 0.05 Ã— d)  for d â‰¤ 15
g(d) = 0                      for d > 15
```

---

## 6. Clinical Translation

### 6.1 Therapeutic Implications

**The Pair Intervention Principle:**

| Strategy | Mechanism | Expected Outcome |
|----------|-----------|------------------|
| Block both PTMs | Prevents pair formation | No shift â†’ No immunity (good for prevention) |
| Block one PTM | Single PTM â†’ Overshoot | Cleared as debris (therapeutic) |
| Restore one PTM | Reverses pair â†’ Single | Overshoot â†’ Clearance (therapeutic) |
| Add third PTM | Triple â†’ Overshoot | Cleared as debris (counterintuitive therapy) |

### 6.2 Diagnostic Applications

**High-Risk Pair Screening:**

1. Identify all R-N, K-R, K-N pairs in patient proteome
2. Filter by span â‰¤ 15 residues
3. Compute predicted Goldilocks probability
4. Rank by combined risk score

### 6.3 Disease-Specific Pair Signatures

| Disease | Primary Pair | Secondary Pairs | Evidence Level |
|---------|--------------|-----------------|----------------|
| Rheumatoid Arthritis | R-N | K-R, K-N | Strong |
| Lupus (SLE) | R-N, K-K | S-K | Moderate |
| Multiple Sclerosis | R-N | K-R | Emerging |
| Type 1 Diabetes | K-R | R-N | Emerging |

---

## 7. Generalization to Any Proteome

### 7.1 Algorithm for New Protein Analysis

```python
def analyze_immunogenic_potential(protein_sequence):
    """
    Compute immunogenic potential for any protein.

    Returns:
        List of (site_pair, goldilocks_probability, risk_score)
    """
    # 1. Find modifiable sites
    sites = find_sites(sequence, residues=['R', 'N', 'K', 'S', 'T'])

    # 2. Generate valid pairs (span â‰¤ 15)
    pairs = [(i, j) for i, j in combinations(sites, 2)
             if abs(i.pos - j.pos) <= 15]

    # 3. Score each pair
    results = []
    for pair in pairs:
        score = f(pair.residues) * g(pair.span) * h(pair.context)
        results.append((pair, score))

    # 4. Return ranked list
    return sorted(results, key=lambda x: -x[1])
```

### 7.2 Proteome-Wide Application

For whole-proteome analysis:

1. **Input:** Any proteome FASTA file
2. **Process:** Apply algorithm to each protein
3. **Output:** Ranked list of immunogenic risk sites
4. **Filter:** By disease context, genetic background, environmental factors

---

## 8. Limitations and Future Work

### 8.1 Current Limitations

1. **Codon encoding approximation:** PTM products (e.g., citrulline) approximated as natural amino acids
2. **Context window:** Fixed 8-residue context may miss long-range effects
3. **Tertiary structure:** 1D analysis doesn't capture 3D proximity
4. **Validation:** Computational predictions require experimental confirmation

### 8.2 Future Directions

1. **AlphaFold integration:** Use 3D structure for true spatial proximity
2. **TCR binding prediction:** Extend to T-cell receptor recognition
3. **Personalized medicine:** Incorporate HLA genotype effects
4. **Multi-omics:** Integrate with expression, localization data

---

## 9. Data Availability

| Resource | Location | Description |
|----------|----------|-------------|
| Analysis scripts | `scripts/25-27_*.py` | PTM combinatorics code |
| Results JSON | `results/hyperbolic/ptm_space_characterization/` | Full analysis output |
| Visualizations | `results/hyperbolic/*/` | PNG figures |
| Encoder model | `models/codon-encoder-3-adic/` | V5.11.3 weights |

---

## 10. Key Equations Summary

| Equation | Name | Use |
|----------|------|-----|
| `S = d_H(Î¼, Î¼') / ||Î¼||` | Relative Shift | Quantify PTM effect |
| `Ïƒ = E(AâˆªB) / [E(A) + E(B)]` | Synergy Ratio | Measure antagonism |
| `Ïƒ = -0.023d + 0.78` | Span-Synergy Law | Predict synergy from distance |
| `0.15 â‰¤ S â‰¤ 0.30` | Goldilocks Criterion | Identify immunogenic range |
| `P = f(R) Ã— g(d) Ã— h(c)` | Goldilocks Probability | Predict immunogenicity |

---

## 11. Conclusion

The non-monotonic PTM response surface represents a fundamental principle of immunogenic potential: **optimal perturbation, not maximal perturbation, creates autoimmune epitopes**. This principle:

1. Explains why single PTMs rarely cause autoimmunity
2. Explains why massive PTM accumulation causes degradation, not immunity
3. Identifies **antagonistic pairs** as the critical immunogenic unit
4. Provides a **computable framework** for predicting autoimmune risk

The framework is **universal**â€”applicable to any human protein in any genetic or disease contextâ€”because it derives from the fundamental geometry of the codon space as encoded in the 3-adic PoincarÃ© ball.

---

## References

1. Ternary VAE V5.11.3 - Native hyperbolic codon embeddings
2. AlphaFold 3 - Structural validation of predictions
3. ACPA epitope mapping - Empirical validation dataset
4. PoincarÃ© ball geometry - Mathematical foundation

---

**Version History:**

| Version | Date | Changes |
|---------|------|---------|
| 1.0 | 2025-12-24 | Initial foundational document |

---

*This document serves as the theoretical foundation for PTM-driven immunogenicity analysis. It is designed to be reusable across diseases, proteins, and genetic backgrounds.*
